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The measurement and understanding of treatment
satisfaction is coming of age; a fact nicely illustrated
by this supplement to Value in Health, which
presents several approaches to the measurement of
treatment satisfaction in multiple diseases. Histori-
cally, researchers working within a business and
marketing framework were the ﬁrst to work with
the satisfaction construct, and have created an
extensive literature on consumer satisfaction. With
respect to health, consumer satisfaction was also the
ﬁrst area of study, where such variables as satisfac-
tion with the physician, overall care, or time kept
waiting were considered in evaluating the overall
quality of care [1]. More recently, treatment satis-
faction has become a focus of study, leading to
the inevitable development of new disease-speciﬁc
measures, such as the OsteoArthritis Treatment Sat-
isfaction Questionnaire [2], a measure of treatment
satisfaction in erectile dysfunction [3], as well as a
broader, generic measure of satisfaction with medi-
cation, the Treatment Satisfaction Questionnaire
Medication [4]. Theoretical work, which ought to
be leading the way in this new ﬁeld, has not kept
pace [5]. I thought bringing together a collection of
articles on the subject of treatment satisfaction
would both move the ﬁeld forward and showcase
the work of Pﬁzer scientists and other colleagues in
this area. Clearly, much remains to be learned about
the concept of treatment satisfaction, both theoret-
ically and empirically, but treatment satisfaction
ought to be considered an important outcome,
when applied selectively, for the evaluation of
medicines.
Treatment satisfaction is a concept that is con-
ceptually distinct from other patient outcomes with
which it is sometimes confused, such as quality of
life, and different predictions arise from working
with it as a result. Satisfaction is inherently among
the most subjective of all constructs, but can it be
measured reliably? Without reliable measurement,
the concept will be useless in making predictions.
All of the articles in this supplement provide evi-
dence that treatment satisfaction can be measured
reliably.
Satisfaction is fundamentally appetitive, yet also
cognitively complex in the case of satisfaction with
medication. It doesn’t require much new thought or
experience, for instance, to know whether one is
satisﬁed with a meal one has eaten—it’s just a gut
feeling. On the other hand, satisfaction with medi-
cation may be inﬂuenced by a variety of factors,
such as whether it works, how strong the side
effects are, whether it restores or interferes with
functioning, is it convenient to take, or even how it
tastes, among others. The evaluation of treatment
satisfaction becomes more difﬁcult when the patient
has no immediate physical sensations they can asso-
ciate with medication effects, such as reduction in
physical symptoms or occurrence of side effects.
Several authors agree that satisfaction is at least
partly a function of prior expectation [5]. This
assertion raises several questions: What else may
drive treatment satisfaction if not expectation, and
how do expectations behave? Does the construct of
treatment satisfaction behave as other patient-
reported outcomes do that may be less related to
expectation?
A strong theoretical understanding of the con-
struct of treatment satisfaction is important because
it will help to generate new ideas for research, and
help regulators and researchers to evaluate empiri-
cal results in the area. There are several important
social scientiﬁc theories that can be mined for
insights related to treatment satisfaction. Before my
ﬁrst project in the area of treatment satisfaction, I
turned to social learning theory (SLT) as developed
by Julian B. Rotter [6]. SLT is of course a broad the-
ory of human behavior, designed to predict behav-
ior across the variety of situations present in human
experience. Rotter’s theory is perhaps best known
for the concept of internal-external locus of control
of reinforcement, which was one of the most widely
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cited and studied concepts in the psychological lit-
erature, and which led to the development of meas-
ures of health locus of control. It is not this
particular application of SLT that was most rele-
vant; rather, it was general predictions about
expectancies that seemed most applicable.
Rotter suggests that one of the predictors of
behavior in a particular situation is expectancy.
There are different types of expectancies and rules
for how they behave. One important distinction is
that there are generalized expectancies and speciﬁc
expectancies. In situations in which one has a sig-
niﬁcant amount of experience, speciﬁc expectancies
relevant to that situation are more likely to operate.
On the other hand, in novel situations, one applies
generalized expectancies, which could have been
developed from other situations or perhaps from
the more general store of one’s experience. Satisfac-
tion has been deﬁned as the correspondence be-
tween one’s actual experience and one’s expected
experience. Herein lies the importance of the insight
from SLT: If one has had a chronic history with a
particular illness and tried many different medica-
tions, one will form a very different kind of ex-
pectation and therefore potentially a different
satisfaction level than if one is trying one’s ﬁrst med-
ication for a newly diagnosed condition. Of course,
this type of process operates across a vast number
of situations that are readily apparent with a little
reﬂection: The example Rotter [7] uses refers to
buying spoiled meat in a market. Whether or not
one returns to the market to buy meat again might
depend on, among other factors, how many times
one has previously bought meat at that particular
market. The prediction of course is that the fewer
the times one has bought meat there, the more one
would be inﬂuenced not to return by a rotten pur-
chase. Another point is that in tasting spoiled meat,
one reaches a threshold of dissatisfaction very
quickly!
When considering medications, what does this
example tell us? One possibility for testing is that
satisfaction with a previously untried medication
might be strongly related to one’s time with symp-
toms of the condition being treated and one’s pre-
vious amount of experience with other treatments.
The more a treatment diverges from the patient’s
past experience, the greater the impact it will have
on satisfaction levels. Obviously, the greatest possi-
ble divergence might occur when the patient has
never tried any treatment before. If the patient suf-
fers bad side effects from a medication they have
never tried before for an illness for which they have
never been treated, they might be so dissatisﬁed they
would not try treatment again. Another hypothesis
to be tested is that valid and stable assessments of
treatment satisfaction might be formed rapidly once
a certain threshold of experience is reached. In the
case of medication, a valid and stable rating of sat-
isfaction can perhaps be obtained once the medica-
tion reaches steady state from a pharmacokinetic/
pharmacodynamic perspective, or the levels rise
into the therapeutic window. Such assessments may
not change much with time, once they have been
formed. Hence, there might be little value in track-
ing satisfaction levels over a long period of time.
Another implication is that there is no such thing as
a premedication baseline level of satisfaction that is
relevant for the evaluation of a medication.
Another source of theory that might be applied
to make useful predictions about treatment satisfac-
tion is prospect theory [8] and its update, cumula-
tive prospect theory [9]. Prospect theory was
developed to address some of the deﬁciencies of
expected utility theory, and concerns itself with how
people make decisions under conditions of uncer-
tainty by valuing certain outcomes, including health
outcomes not yet experienced [10]. To the extent
that satisfaction with medication results from the
value achieved through effective treatment, some of
the predictions about valuation under conditions of
uncertainty from prospect theory may also be rele-
vant to value as experienced. There may be several
useful predictions from prospect theory that could
be tested in the context of the measurement of treat-
ment satisfaction. First, the value of a change in an
outcome is not consistent across the spectrum of
possible outcomes, but is much more dramatic at
either extreme end of the spectrum. For example,
if one is completely asymptomatic and in vibrant
health, the presence of a mild symptom would be
much more distressing than it would be if the same
symptom occurred on top of several other symp-
toms or closer to the middle of the range of health
states. Another prediction from prospect theory is
that losses are given much more importance than
gains of the same magnitude. A reduction in satis-
faction would be more important to the patient
than a gain of the same magnitude. Of course, these
predictions from prospect theory need to be borne
out empirically in the study of treatment satisfac-
tion. They do potentially have an impact, however,
in how results from treatment satisfaction studies
are interpreted.
Yet another potential source of theory-based pre-
dictions about the way satisfaction operates are
insights on how well-being functions, as described
by Sirgy [11]. He suggests that people seek to max-
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imize well-being by having positive experiences, but
only to a certain extent, because frequent positive
experiences contribute more to long-term well-
being than intense positive experiences do. As a
result, there is a threshold of well-being past which
most individuals do not wish to go, because that
would raise the adaptation level, and the higher
the adaptation level, the greater the likelihood that
future events will be judged as less satisfying. Might
there also be a level of satisfaction with medication
treatment that would be enough? In other words, is
there a satisfaction threshold? If so, what would be
the importance of that in the evaluation of medi-
cines and how satisfaction is measured?
These collected observations from SLT, prospect
theory, and theories of well-being have implications
for clinical trial design. First, to help control for dif-
ferent levels of experience with medication, a cross-
over design is optimal, so that at least every trial
participant experiences all of the treatments (this
would suggest that the assessment of satisfaction
may not be best performed in a dose-ranging study,
as a result of the complexity of the crossover). This
design also helps to create a baseline of shared expe-
rience among trial subjects. Another implication is
that satisfaction should not be measured when
treatment begins, but should be delayed until the
time that the medication reaches therapeutic levels
(at minimum) and has had time to take effect.
Another implication is that prior experience with
medication for the condition under study, and the
length of time with the condition, should both be
measured and used as a covariate in analyses of sat-
isfaction as an endpoint.
In addition to the importance of expectations,
research with the concept of satisfaction has shown
that overall treatment satisfaction is affected by a
number of other variables, such as medication efﬁ-
cacy, side effects and tolerability, level of function-
ing, and convenience [4]. There may be other
factors as well, such as taste and cost, but the most
important determinant of satisfaction appears to be
how well the drug works.
Of course treatment satisfaction can’t trump the
endpoints of efﬁcacy, safety, mortality, tolerability,
and so forth, which we have always used to evalu-
ate new medicines and will continue to do. But as
the hurdles to developing new products get higher,
and an increasing number of markets have generic
competition or at least multiple treatment alterna-
tives, satisfaction can be an important variable to
assist in product differentiation [12]. By measuring
treatment satisfaction, we can bring another aspect
of the patient’s experience to the evaluation of new
and existing medicines and other treatments. The
patient’s perspective has become increasingly im-
portant over the last several decades and has led to
the rapid growth of the ﬁeld of patient-reported
outcomes and quality-of-life assessment, not to
mention increasing empowerment of the consumer
within the healthcare system. And it will remain
important, particularly as the healthcare system
will require greater copayments and increased
ﬁnancial contributions from patients in the pur-
chase of their care. Treatment satisfaction can be a
very important way in which patients will be able
to differentiate between similar products and iden-
tify value worth paying for. Nevertheless, without
theoretical advances and a rigorous approach to
the measurement of satisfaction, the ﬁeld will not
move forward. It is my hope that the work pre-
sented by my colleagues in this supplement of
Value in Health will help to stimulate the growth
of the ﬁeld of the scientiﬁc measurement of treat-
ment satisfaction.
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